<DOC>
	<DOCNO>NCT01864993</DOCNO>
	<brief_summary>Non Celiac Gluten Sensitivity ( NCGS ) emergent syndrome mainly induce gastrointestinal symptom . NCGS suspect present 6 % population thus represent important issue health care . Actually remain difficult diagnose prove due lack establish criterion . The investigator intention establish diagnostic flowchart evaluate real impact NCGS cohort patient suffer functional gastrointestinal symptom .</brief_summary>
	<brief_title>Symptomatic Response Gluten Challenge Patients With Suspected Non Celiac Gluten Sensitivity</brief_title>
	<detailed_description>The propose study design randomise double-blind multicenter clinical trial crossover . The Coordinating Center `` Centro per la Prevenzione e la Diagnosi della Malattia Celiaca '' , Fondazione IRCCS Ca ' Granda - Ospedale Maggiore Policlinico , Milano . Secondary enrollment center Italian Gastroenterology Units outpatient service . Enrollment criterion diagnosis irritable bowel syndrome ( IBS ) functional dyspepsia . Patients functional gastrointestinal disorder include group `` Functional non specific gastrointestinal symptom '' . After give write informed consent , patient undergo diagnostic work-up recommend case suspect irritable bowel symptoms/functional dyspepsia aim exclusion CD allergy alimentary antigen mean serological testing ( anti transglutaminase antibody ) skin test , gastrointestinal disease . Endoscopic , histologic and/or image exam together supplemental blood test prescribe individual case accord international guideline . Enrolled subject ask fill - checklist evaluation psychological profile ( SCL90 questionnaire , particular aim evaluating level anxiety , depression somatisation ) ; - questionnaire perceive level physical mental health ( SF36 questionnaire ) ; - Ten centimeter long visual analogue scale ( VAS ) level satisfaction health status intensity single symptom . At end present phase patient start GFD subsequent three week . At end GFD period patient fill VAS SF36 . Only patient present 30 % increase global VAS score ( `` GFD Responders '' ) continue study . Conversely , non responder consider `` non gluten sensitive '' finish trial . Responders GFD period entry randomisation phase undergo double-blind stimulation test cross . Patients randomise assume gluten placebo 7 day . After treatment patient fill VAS SF36 . A diagnosis NCGS ascertain case symptomatic response limit gluten ingestion .</detailed_description>
	<mesh_term>Hypersensitivity</mesh_term>
	<criteria>Subjects gastrointestinal functional disorder ( irritable bowel syndrome , functional dyspepsia unspecified functional gastrointestinal symptom ) Celiac disease Alimentary allergies Inflammatory bowel disease Major abdominal surgery Psychiatric disorder Neoplasia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>non celiac gluten sensitivity</keyword>
	<keyword>gluten</keyword>
	<keyword>irritable bowel syndrome</keyword>
	<keyword>functional disorder</keyword>
</DOC>